MA56114A - Composés pour le traitement de troubles dépendant de la kinase - Google Patents

Composés pour le traitement de troubles dépendant de la kinase

Info

Publication number
MA56114A
MA56114A MA056114A MA56114A MA56114A MA 56114 A MA56114 A MA 56114A MA 056114 A MA056114 A MA 056114A MA 56114 A MA56114 A MA 56114A MA 56114 A MA56114 A MA 56114A
Authority
MA
Morocco
Prior art keywords
kinase
compounds
treatment
dependent disorders
disorders
Prior art date
Application number
MA056114A
Other languages
English (en)
Inventor
Lynne Canne Bannen
Minna Bui
Faming Jiang
Kin Tso
Yong Wang
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA56114A publication Critical patent/MA56114A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056114A 2019-06-04 2020-06-03 Composés pour le traitement de troubles dépendant de la kinase MA56114A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962856920P 2019-06-04 2019-06-04

Publications (1)

Publication Number Publication Date
MA56114A true MA56114A (fr) 2022-04-13

Family

ID=71842789

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056114A MA56114A (fr) 2019-06-04 2020-06-03 Composés pour le traitement de troubles dépendant de la kinase

Country Status (10)

Country Link
US (1) US12503438B2 (fr)
EP (1) EP3980404A1 (fr)
JP (1) JP7820152B2 (fr)
CN (1) CN114040912B (fr)
AR (1) AR119069A1 (fr)
AU (1) AU2020289324A1 (fr)
CA (1) CA3139156A1 (fr)
MA (1) MA56114A (fr)
TW (1) TWI850394B (fr)
WO (1) WO2020247418A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY210421A (en) * 2018-01-26 2025-09-22 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN114573553B (zh) * 2022-01-27 2023-11-10 广州六顺生物科技有限公司 杂芳环类衍生物及其制备方法和应用
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
CN116271008A (zh) * 2022-12-30 2023-06-23 广东天普生化医药股份有限公司 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392565B1 (fr) 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
CA2604238C (fr) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
EP1989211A2 (fr) 2006-01-30 2008-11-12 Array Biopharma, Inc. Composés hétérobicycliques de thiophène et leurs méthodes d'utilisation
EP2423208A1 (fr) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Composants actifs pharmaceutiquement en tant qu'inhibiteurs Axl
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CA2886433C (fr) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
EP3906921A1 (fr) * 2014-04-25 2021-11-10 Exelixis, Inc. Procédé de traitement de l'adénocarcinome pulmonaire
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
CN107235896B (zh) 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
TW201940473A (zh) * 2017-12-20 2019-10-16 美商安捷克斯製藥公司 作為多激酶抑制劑的胺基碳酸鹽及尿素化合物
MY210421A (en) * 2018-01-26 2025-09-22 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
WO2019160813A1 (fr) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole en tant qu'agonistes de fxr et leurs procédés d'utilisation

Also Published As

Publication number Publication date
CN114040912B (zh) 2024-10-25
US20230043835A1 (en) 2023-02-09
TW202110806A (zh) 2021-03-16
US12503438B2 (en) 2025-12-23
WO2020247418A1 (fr) 2020-12-10
AU2020289324A1 (en) 2021-12-16
JP7820152B2 (ja) 2026-02-25
CN114040912A (zh) 2022-02-11
JP2022535108A (ja) 2022-08-04
TWI850394B (zh) 2024-08-01
EP3980404A1 (fr) 2022-04-13
AR119069A1 (es) 2021-11-24
CA3139156A1 (fr) 2020-12-10

Similar Documents

Publication Publication Date Title
MA51673A (fr) Composés destinés au traitement de troubles dépendant de la kinase
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3968996A4 (fr) Composés triaryles pour le traitement de maladies pd-l1
EP3935050A4 (fr) Composés hétérocycliques pour traitement médical
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA56114A (fr) Composés pour le traitement de troubles dépendant de la kinase
EP3841086A4 (fr) Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
EP3774743C0 (fr) Composés de type promédicaments activés par akr1c3 et leur utilisation pour le traitement de troubles hyperprolifératifs
EP3941462A4 (fr) Composés pharmaceutiques pour le traitement de troubles médiés par le complément
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3938340A4 (fr) Dérivés aromatiques hétérobicycliques et hétéroaromatiques pour le traitement de troubles liés à la ferroptose
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
MA51738A (fr) Composés pour le traitement de la douleur
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3805216A4 (fr) Composés pour le traitement ou la prévention de maladies hépatiques
EP3877382A4 (fr) Nouveaux composés pour le traitement de maladies respiratoires
MA51679A (fr) Composés destinés au traitement de troubles dépendant de la kinase
EP3737750A4 (fr) Agents de phosphatase alcaline pour le traitement de troubles neurodéveloppementaux
EP4021480A4 (fr) Peptides pour le traitement de troubles rénaux
EP3990458A4 (fr) Composés pour le traitement du cancer
MA56501A (fr) Composés destinés au traitement de troubles neuromusculaires
EP4054567A4 (fr) Traitement de troubles hépatiques